Sarbaugh Keith, an Executive Vice President at Zoetis Inc., has reported a transaction involving phantom stock units. This filing, dated October 13, 2026, is significant as it reflects the company's ongoing strategies to align executive compensation with company performance.
Zoetis Inc. is a prominent player in the pharmaceutical preparations industry, focusing on animal health products. The company is known for its innovative solutions and commitment to improving the health of pets and livestock. The recent filing is part of a series of disclosures by Sarbaugh, indicating a pattern of activity related to his compensation.
According to the filing, Sarbaugh acquired 303.4903 phantom stock units on October 9, 2026, at a price of $26.17 per unit. Following this transaction, he now holds a total of 2,668.3214 shares. The phantom stock units are part of the Zoetis Supplemental Savings Plan, which allows for cash settlement upon separation from service. Additionally, these units can be transferred into alternative investment funds, subject to certain limitations by Zoetis.
This update may affect various stakeholders, including Zoetis employees and investors, as it highlights the company's approach to executive compensation. Such strategies are crucial for attracting and retaining top talent in the competitive pharmaceutical sector.
The filing does not specify what happens next regarding Sarbaugh's transactions or any potential changes in executive compensation policies.